Corline Biomedical AB AI Stock Analysis
Want to see SE:CLBIO full AI Analyst Report?
Corline Biomedical AB (CLBIO) AI Stock Analysis
Corline Biomedical AB
(Nasdaq OMX AB:CLBIO)
The score is held back primarily by weak financial performance: Corline Biomedical is loss-making, burns roughly SEK 15m of cash per year, has negative gross profit and reports small, erratic milestone-based revenue, all of which point to continued reliance on external funding and dilution risk. The main strength is a debt-free balance sheet with ~87% equity-to-assets, alongside improving TTM revenue (+25%), a narrower net loss and lower capital spending. Technicals add little support, with the price below all major moving averages and RSI near oversold levels. Valuation offers no cushion given negative earnings and no dividend. Earnings call and corporate events were excluded due to missing data, with their weight redistributed across the remaining components.
Corline Biomedical AB (CLBIO) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 365.86M
- Dividend Yield
- ―
- Average Volume (3M)
- 16.32K
- Price to Earnings (P/E)
- -26.3
- Beta (1Y)
- 0.47
- Revenue Growth
- 77.77%
- EPS Growth
- 47.65%
- Country
- Sweden
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Corline Biomedical AB Business Overview & Revenue Model
Company Description
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative med...
How the Company Makes Money
Corline Biomedical makes money primarily by commercializing its blood-compatible biomaterial and surface-technology solutions through product sales and B2B collaborations. Key revenue streams typically include: (1) Sales of proprietary products/consu...
Corline Biomedical AB Financial Statement Overview
Summary
Corline Biomedical shows the typical early-stage biotech profile: a debt-free balance sheet (equity of about SEK 99.0m against SEK 114.2m of assets, ~87% equity-to-assets) funding a business that is not yet profitable or cash-generative. The income statement is weak (score 27) with small, milestone-driven revenue that has swung from SEK 25.0m in 2023 to SEK 7.7m in 2025, a TTM net loss of SEK 12.3m on SEK 12.4m of revenue, and negative gross profit. Cash flow is weaker still (score 20), with TTM operating and free cash flow of roughly negative SEK 14.4m and SEK 14.8m and negative free cash flow in every year shown. The balance sheet (score 72) offsets some of this risk, but equity is being eroded by losses and sustained through shareholder funding, implying recurring dilution risk. Encouraging signs include ~25% TTM revenue growth, a narrower loss versus 2024 and 2025, and sharply reduced capital spending.
Income Statement
27NegativeBalance Sheet
72PositiveCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.39M | 7.65M | 9.78M | 25.03M | 23.55M | 7.06M |
| Gross Profit | 4.87M | -14.21M | 13.44M | 28.38M | 22.73M | 9.10M |
| EBITDA | -12.23M | -14.12M | -23.07M | -1.69M | 2.38M | -6.88M |
| Net Income | -12.32M | -14.71M | -23.19M | -1.81M | 2.33M | -6.92M |
Balance Sheet | ||||||
| Total Assets | 114.18M | 98.58M | 94.76M | 100.11M | 101.78M | 101.66M |
| Cash, Cash Equivalents and Short-Term Investments | 32.99M | 20.56M | 17.67M | 17.01M | 26.21M | 41.63M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 15.18M | 4.82M | 7.85M | 6.79M | 7.19M | 9.43M |
| Stockholders Equity | 99.00M | 93.76M | 86.91M | 93.32M | 94.59M | 92.23M |
Cash Flow | ||||||
| Free Cash Flow | -14.85M | -17.74M | -16.14M | -9.73M | -15.45M | -14.45M |
| Operating Cash Flow | -14.44M | -17.69M | -8.64M | 886.00K | -6.45M | -4.83M |
| Investing Cash Flow | -750.00K | -982.00K | -7.50M | -10.62M | -9.00M | -9.56M |
| Financing Cash Flow | 39.87M | 21.56M | 16.79M | 537.00K | 26.00K | 47.13M |
Corline Biomedical AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLBIO, the sentiment is Negative. The current price of 14.00 is above the 20-day moving average (MA) of 13.84, below the 50-day MA of 14.10, and below the 200-day MA of 16.19, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 49.99 is Neutral, neither overbought nor oversold. The STOCH value of 60.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLBIO.
Corline Biomedical AB Peers Comparison
Overall Rating
SE:HNSA60Neutral
SE:NXTCL46Neutral
SE:SPAGO42Neutral
SE:CLBIO42Neutral
SE:FLUO40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | SEK 4.82B | -5.71 | ― | ― | 68.88% | 10.63% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | SEK 30.33M | -0.57 | -81.23% | ― | -4.02% | 35.86% | |
| 42Neutral | SEK 33.21M | -1.03 | -87.37% | ― | -97.52% | 31.31% | |
| 42Neutral | SEK 375.01M | -26.29 | ― | ― | 77.77% | 47.65% | |
| 40Underperform | SEK 482.30M | -6.55 | ― | ― | ― | -23.57% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:CLBIO | Corline Biomedical AB | 14.00 | -5.05 | -26.51% | |
| SE:HNSA | Hansa Biopharma | 45.14 | 16.40 | 57.06% | |
| SE:NXTCL | NextCell Pharma AB | 0.22 | -0.53 | -71.07% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.05 | -56.84% | |
| SE:BIOWKS | Bio-Works Technologies AB | 2.91 | 0.39 | 15.48% | |
| SE:FLUO | FluoGuide A/S | 29.50 | -8.50 | -22.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026
